Our Keynote hematology clinical trials are studying pembrolizumab to see if it may help patients with hematological cancers. Pembrolizumab is an investigational immunotherapy that targets the PD-1 pathway.
Pembrolizumab has been FDA-approved for use in certain types of cancer.
If your patients have one of the conditions we are studying, you may want to consider a Keynote trial.
Clinical trials for various hematological cancers are underway. To see if your patients qualify for one of these trials, contact our clinical trial information center at 1-888-577-8839. If you are interested in partnering with us as an investigator, call 1-800-290-4339.
|Trial Description||Keynote Trial||Condition||Phase||Status|
|Study of Pembrolizumab vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma||204||Hodgkin Lymphoma||Phase 3||Recruiting|
|Safety and Efficacy of Pembrolizumab in Children and Young Adults With Classical Hodgkin Lymphoma||667||Hodgkin Lymphoma||Phase 2||Recruiting|
|Study of Pembrolizumab in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome||170||
||Phase 2||Active, not recruiting|
|Study of Pembrolizumab in Combination With Dinaciclib in Hematologic Malignancies||155||
|A Trial of Pembrolizumab in Participants With Blood Cancers||013||
||Phase 1||Active, not recruiting|
|A Study of Pembrolizumab in Combination With Standard of Care Treatments in Participants With Multiple Myeloma||023||Multiple Myeloma||Phase 1||Active, not recruiting|
|Study of Pembrolizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma||087||Hodgkin Lymphoma||Phase 2||Active, not recruiting|